Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 279 recommendations for 81 medicines and 19 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
8. Immunomodulators and antineoplastics
  1. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  2. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
  3. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  4. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  5. Allopurinol General information
    Section
    Supportive medicines
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  6. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  7. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  8. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  9. Azathioprine General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 50 mg (scored); 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  10. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  11. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  12. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
    Indications
    Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis
  13. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  14. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon
  17. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  18. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  19. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  21. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid: 25 mg; 50 mg
    • Oral > Solid: 25 mg; 50 mg tablet
    Indications
    Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  23. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  25. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  26. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Acute myeloid leukaemia with recurrent genetic abnormalities
  27. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Indications
    Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  28. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate
  29. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of breast Lymphoid leukaemia, not elsewhere classified Other specified malignant neoplasms of breast Diffuse large B-cell lymphomas Plasma cell myeloma Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  30. Enzalutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate
  31. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  32. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  33. Etoposide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  34. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)
    Indications
    Other specified gliomas of brain
  35. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  36. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  38. Flutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  39. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  40. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  41. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  42. Goserelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  43. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
  44. Hydroxycarbamide (hydroxyurea) General information
    Section
    Cytotoxic medicines
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  45. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  48. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  49. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  50. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  51. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  52. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  53. Mercaptopurine General information
    Section
    Cytotoxic medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 50 mg tablet
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis
  56. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
  57. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  58. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  59. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Melanoma of skin
  60. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  62. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  63. Pembrolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab for Melanoma of skin
  65. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis
  66. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  67. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
    Indications
    Tumour lysis syndrome
  68. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  69. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas
  70. Tacrolimus General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  71. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  72. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  73. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  74. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  75. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  78. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site
  79. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow